Impact of U.S.-Canada Trade Talks Collapse on Market Dynamics: What Investors Need to Know
The collapse of U.S.-Canada trade talks and new tariffs raise concerns for investors. Here's what you need to know.
Moderna's Cancer Vaccine Breakthrough: Implications for Investors and Biotech Traders
The recent Phase 3 trial results for Moderna's cancer vaccine have sent shockwaves through the biotech sector, raising investor sentiment dramatically…
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
Bunker Hill Mining and Silver47 Merger: A New Player in Critical Minerals
Bunker Hill Mining and Silver47 Exploration unite in a $163M all-stock deal, reshaping the critical minerals landscape.
Capricor Therapeutics Faces PDUFA Date: What Investors Should Know
Capricor's stock dropped nearly 8% as it awaits an FDA decision on Deramiocel for Duchenne muscular dystrophy.
Moderna's Cancer Vaccine Triumph: What This Means for Investors
Moderna's stock surged 176.97% after successful Phase 3 trial results for its cancer vaccine, signaling potential market…
Bunker Hill Mining (BNKR) and Silver47 (AGA) Merge to Create a Silver Powerhouse
Bunker Hill Mining and Silver47 unite in a $163M all-stock merger, aiming to bolster silver production in North America.
Werewolf Therapeutics (HOWL) and Ambros Therapeutics Join Forces in Strategic Merger
Werewolf Therapeutics and Ambros Therapeutics announce an all-stock merger and a $150 million private placement, focusin…
TG Therapeutics (TGTX) Sees Stock Surge Amid Acquisition Buzz
TG Therapeutics is gaining traction as speculation about a potential acquisition heats up, fueled by its drug BRIUMVI's …
Werewolf Therapeutics and Ambros Therapeutics Join Forces: Implications for Oncology Investors
A strategic merger between Werewolf and Ambros Therapeutics aims to enhance oncology therapeutics, raising $150 million …
Bunker Hill Mining and Silver47 Merge: A New Force in North American Silver and Critical Minerals
Bunker Hill Mining and Silver47 have merged in a $163M all-stock deal, positioning themselves as leaders in critical min…
Bristol Myers Squibb's ZENBEXUS Approval: A Strategic Move in Oncology
Bristol Myers Squibb's ZENBEXUS receives FDA approval, marking a significant step in oncology and investor interest.